Conference abstract · 26 Oct 2015
Conference abstractPublished 15 May 2017
CMC considerations for biosimilar drug development
Protagen Protein Services, Germany; University of La Sabana, Colombia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The scope of this speech is to show a general consideration regarding the evaluation of immunogenicity in bio-therapeutic products. Biological drugs and their biosimilars are highly complex molecules derived from living cells or organisms. The success of biological drugs has been focused on unwanted immunogenicity of these products. Evaluation of unwanted immunogenicity is an important consideration in development of bio-therapeutics products. Immunogenicity to protein based biological drugs is a complex process that involves numerous factors such as general patient´s immunity, amino-acid sequence of proteins, as well as biological drugs formulation (i.e. protein aggregates, impurities or excipients improper choice) and the drug administration. With new platforms, new technologies and development of novel therapeutics and treatment modalities, the assessment of immunogenicity will continue to require products approved on safety as well as on efficacy perspectives. Correlation between immunogenicity and clinical sequelae entirely depends on the appropriate detection, measurement and characterization of antibodies against biological therapeutics. These include conventional approaches such as ELISA and radioimmunoprecipitation assays. Alternative technologies use instruments based in nanobiosensors as surface plasmon resonance (SPR) and quartz crystal microbalances (QCM) to detect and characterize antibodies against therapeutic proteins and other molecular interactions. The purpose of this presentation is to show a general overview on the ability to detect therapeutic induced antibodies in plasma and sera of treated patients with biological drugs, using nanobiosensors. The evaluation, safety and efficacy of biosimilars require more rigorous testing than conventional generic drugs. The profiles of biosimilars must demonstrate similar physicochemical and biological characteristics, efficacy and safety in accordance with the approval requirements of regulatory authorities.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract
Developing biosimilars: Considerations, opportunities and challenges
Conference abstract · 16 Sep 2020
Biosimilar Drug Development and Approval Process
Review article · 1 Oct 2019
Biosimilar Drug Development and Approval Process
Conference abstract · 15 Apr 2019
Sample size in biosimilar drug product development
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ulrike Konrad”
- BylineArticles whose byline prints “Rosa Helena Bustos”
